Latest period
$676.00M
YoY change
-100.0%
5Y CAGR
-100.0%
Peak year (2021)
$1.18B
Latest annual
$0.00
Stock-Based Compensation history chart for Pfizer (PFE) from 1989 to 2025
Latest: $0.00
Stock-Based Compensation growth chart for Pfizer (PFE) from 1989 to 2025
Latest: -100.0%
Stock-Based Compensation history table for Pfizer (PFE) from 1989 to 2025
| 2025 | $0.00 | -100.0% | −$877.00M | ||
| 2024 | $877.00M | +67.0% | +$352.00M | ||
| 2023 | $525.00M | -39.8% | −$347.00M | ||
| 2022 | $872.00M | -26.2% | −$310.00M | ||
| 2021 | $1.18B | +56.3% | +$426.00M | ||
| 2020 | $756.00M | +5.3% | +$38.00M | ||
| 2019 | $718.00M | -24.3% | −$231.00M | ||
| 2018 | $949.00M | +13.0% | +$109.00M | ||
| 2017 | $840.00M | +21.6% | +$149.00M | ||
| 2016 | $691.00M | +3.3% | +$22.00M | ||
| 2015 | $669.00M | +14.2% | +$83.00M | ||
| 2014 | $586.00M | +12.0% | +$63.00M | ||
| 2013 | $523.00M | +8.7% | +$42.00M | ||
| 2012 | $481.00M | +14.8% | +$62.00M | ||
| 2011 | $419.00M | +3.5% | +$14.00M | ||
| 2010 | $405.00M | +16.0% | +$56.00M | ||
| 2009 | $349.00M | — | +$349.00M | ||
| 2008 | $0.00 | — | $0.00 | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | $0.00 | ||
| 2005 | $0.00 | — | $0.00 | ||
| 2004 | $0.00 | — | $0.00 | ||
| 2003 | $0.00 | — | $0.00 | ||
| 2002 | $0.00 | — | $0.00 | ||
| 2001 | $0.00 | — | $0.00 | ||
| 2000 | $0.00 | — | $0.00 | ||
| 1999 | $0.00 | — | $0.00 | ||
| 1998 | $0.00 | — | $0.00 | ||
| 1997 | $0.00 | — | $0.00 | ||
| 1996 | $0.00 | — | $0.00 | ||
| 1995 | $0.00 | — | $0.00 | ||
| 1994 | $0.00 | — | $0.00 | ||
| 1993 | $0.00 | — | $0.00 | ||
| 1992 | $0.00 | — | $0.00 | ||
| 1991 | $0.00 | — | $0.00 | ||
| 1990 | $0.00 | — | $0.00 | ||
| 1989 | $0.00 | — | — |
- 2025$0.00-100.0%
- 2024$877.00M+67.0%
- 2023$525.00M-39.8%
- 2022$872.00M-26.2%
- 2021$1.18B+56.3%
- 2020$756.00M+5.3%
- 2019$718.00M-24.3%
- 2018$949.00M+13.0%
- 2017$840.00M+21.6%
- 2016$691.00M+3.3%
- 2015$669.00M+14.2%
- 2014$586.00M+12.0%
- 2013$523.00M+8.7%
- 2012$481.00M+14.8%
- 2011$419.00M+3.5%
- 2010$405.00M+16.0%
- 2009$349.00M—
- 2008$0.00—
- 2007$0.00—
- 2006$0.00—
- 2005$0.00—
- 2004$0.00—
- 2003$0.00—
- 2002$0.00—
- 2001$0.00—
- 2000$0.00—
- 1999$0.00—
- 1998$0.00—
- 1997$0.00—
- 1996$0.00—
- 1995$0.00—
- 1994$0.00—
- 1993$0.00—
- 1992$0.00—
- 1991$0.00—
- 1990$0.00—
- 1989$0.00—
Stock-Based Compensation values are taken from Pfizer's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Pfizer (PFE)
Stock-Based Compensation for Pfizer (PFE): headline value $676.00M · YoY -100.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual stock-based compensation for Pfizer (PFE) came in at $0.00 – plunged 100.0% year-over-year.
Over 2020–2025 (5 years), Pfizer stock-based compensation expanded at a -100.0% compound annual rate, with a net decline across the window.
$1.18B stands as the all-time-high annual stock-based compensation, posted in 2021, against a low of $0.00 during 1989.
Pfizer Stock-Based Compensation by Year
Pfizer Stock-Based Compensation 2025: $0.00
Pfizer stock-based compensation in 2025 was $0.00, plunged 100.0% below 2024.
Pfizer Stock-Based Compensation 2024: $877.00M
2024's stock-based compensation for Pfizer came in at $877.00M, surged 67.0% from 2023.
Pfizer Stock-Based Compensation 2023: $525.00M
Pfizer posted stock-based compensation of $525.00M in 2023, plunged 39.8% below 2022.
Pfizer Stock-Based Compensation 2022: $872.00M
In 2022, Pfizer reported stock-based compensation of $872.00M, declined 26.2% below 2021.
Pfizer Stock-Based Compensation 2021: $1.18B
Pfizer stock-based compensation in 2021 was $1.18B.
See more financial history for Pfizer (PFE).
Sector peers by Stock-Based Compensation
Healthcare peers of Pfizer (PFE), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation